WittGen Inc.

Based in the US, WittGen Inc. is a generative biotechnology company specializing in advanced clinical development through innovative profiling technology, aimed at enhancing patient stratification for oncology research. WittGen Inc. , founded in 2023, is located in Berkeley, California, USA.

The company focuses on advanced clinical development solutions and was established by a team of experienced professionals in the biotechnology field. In May 2026, WittGen Inc. raised an undisclosed amount from new investor Digital Healthcare Partners, with participation from returning investor Nautilus Investment. WittGen specializes in advanced clinical development through its flagship Virtual Cell-to-Patient profiling technology, which employs Single-Cell GenAI to provide unparalleled insights into patient stratification.

The core offering enables clinical leaders to derive actionable therapeutic insights from large-scale analysis of archived bulk RNA samples and pathological image data, such as H&E and IHC. This innovative approach bridges the gap between complex raw data and practical clinical applications, allowing for the identification of potential responder populations with significantly enhanced precision—up to seven times higher than traditional methods. WittGen's technology is validated across more than five cancer types, catering primarily to pharmaceutical companies and academic institutions engaged in oncology research and drug development. The company markets its solutions globally, with a focus on North America, Europe, and select markets in Asia, where there is a growing demand for efficient and cost-effective patient stratification solutions.

WittGen generates revenue through partnerships and direct transactions with pharmaceutical companies and academic research institutions, leveraging its Virtual Cell technology as a service. The revenue model is structured around providing comprehensive patient profiling solutions, with pricing based on project scope and the volume of samples processed. Clients typically engage WittGen for specific research initiatives, such as clinical trial de-risking or biomarker discovery, and may enter into agreements for ongoing collaborations or one-time projects. The company offers distinct services that include large-scale patient profiling at a fraction of the cost of traditional single-cell approaches, positioning itself as a cost-effective option for organizations seeking to optimize their research outcomes.

WittGen aims to expand its offerings by developing new solutions that enhance patient stratification efficiency, targeting a launch within the next 12-18 months. The company is also looking to penetrate additional markets in Europe and Asia, aiming for significant growth by 2025. Recent funding will be allocated to support product development and regional expansion, helping to establish WittGen's presence in these strategic areas.